Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 inhaled nitric oxide study in cystic fibrosis patients with Mycobacterium abscessus infection
MOH_2017-07-17_000637Phase 2Completed
- Sponsor
- Advanced Inhalation Therapies
- Start
- Jun 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nitric oxide in nontuberculous mycobacterial lung disease, Mycobacterium abscessus disease and cystic fibrosis (CF), sponsored by Advanced Inhalation Therapies. Primary endpoints: Efficacy of inhaled nitric oxide, Safety of inhaled nitric oxide and 1 more. Started Jun 2017; status: completed.
02
Drugs
nitric oxide
03
Conditions
nontuberculous mycobacterial lung diseaseMycobacterium abscessus diseasecystic fibrosis (CF)
Beyond the preview
Go deeper on MOH_2017-07-17_000637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-07-17_000637.